Navidea Biopharmaceuticals, Inc., formerly Neoprobe Corp., is a biopharmaceutical company focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer.
The company’s recently announced name change (effective Jan. 5, 2012) reflects the company’s focus on the precision diagnostics space where it will pursue development of innovative technology into products to advance patient care. Continued efforts will center on obtaining approval and commercialization of Lymphoseek® and on the development of RIGScan™, the company’s two radiopharmaceutical agent platforms.
Navidea’s plan of action is to move forward with development opportunities, including in-licensing and acquisition of other promising agents. The company recently in-licensed exclusive worldwide rights from AstraZeneca for AZD4694, the company’s drug candidate for aiding in the diagnosis of Alzheimer’s disease.
Key Investment Highlights
• Strategic in-licensing plan positions company for growth and expansion of its precision radiopharmaceutical pipeline
• Rebranding strategy permits greater management and resource focus on substantial opportunity for growth and increased stockholder value
• Methodical plan to grow its pharmaceutical business and capitalize on radiopharmaceuticals, with industry sales forecast to grow to $5.4 billion by 2015
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html